ESR1 and breast carcinoma: It provides the 10-year likelihood of breast cancer recurrence and helps to predict the likelihood of benefit from chemotherapy in patients diagnosed with early-stage estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2−) breast cancer.